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ABSTRAK
Hormon estrogen memiliki peran penting dalam pengaturan metabolisme lemak. Studi terbaru menunjukan 
bahwa pemberian estrogen dapat menghambat lipolisis. Meskipun demikian, informasi mengenai proses 
molekuler yang terlibat pada fenomena ini masih sangat terbatas. Review ini bertujuan untuk menyajikan 
informasi mengenai berbagai macam penelitian yang menghubungkan efek dari estrogen terhadap lipolisis 
jaringan adiposa dan jalur molekuler yang terlibat dalam proses ini. Diperkirakan bahwa efek dari kerja estrogen 
terhadap penghambatan lipolisis terjadi akibat aktivasi estrogen receptor alpha (ER-α) di jaringan adiposa. 
Hal ini didukung oleh hasil penelitian yang menunjukan bahwa hewan coba yang tidak dapat mengekspresikan 
gen ESR1 memiliki penumpukan lemak yang berlebihan. Sebagai tambahan, berdasarkan studi yang dilakukan 
pada manusia diketahui bahwa ekspresi ESR1 di jaringan adiposa berhubungan terbalik dengan indeks massa 
tubuh.  Penelitian lebih lanjut diharapkan dapat menguji peran ER-α terhadap lipolysis di jaringan adiposa 
terutama untuk melihat variasi respon ER-α terhadap program penurunan berat badan. Selain itu, ER-α juga 
dapat digunakan sebagai target pengembangan terapi farmakologis dan nutrisional untuk penurunan berat 
badan di masa depan. 
Kata kunci: jaringan adiposa, estrogen, reseptor estrogen, lipolisis, obesitas, wanita.
ABSTRACT
Estrogen has an important role in regulation of fat metabolism. Recent studies indicated that this process 
occurred due to inhibition of lipolysis by external estrogen administration. However, there was limited information 
regarding molecular process responsible for this phenomenon. This paper was aimed to present a brief update 
on recent studies explaining the effect of estrogen on adipose tissue lipolysis and the molecular pathway involved 
in this process.  It is suggested that the effect of estrogen to reduction of lipolysis was through activation of 
estrogen receptor alpha (ER-α) in adipose tissue. This finding is supported by the fact that mice lacking of ESR1 
gene (encodes ER-α) accumulate more fat and ESR1 mRNA in human adipose tissue was inversely correlated 
with body mass index (BMI). Future study should be aimed to clarify the role of ER-α on lipolysis in adipose 
tissue during weight loss intervention. Additionally, new pharmacological or nutritional treatment with ability 
to modulate ER-α activity/expression could be used as a potential weight loss intervention.
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INTRODUCTION
Obesity is an increasing pandemic that 
affects humans worldwide and World Health 
Organization (WHO) reported that more than 500 
million people over 20 years old were obese in 
2008.1 The expert panel of WHO recommends 
10% weight loss for obese and overweight 
individuals especially by lifestyle intervention.2 
A lifestyle intervention including diet, physical 
activity and behaviour modification was able 
to help reducing weight loss for some obese 
individuals, could not be applied to everyone.3 
Furthermore, with the fact that prevalence of 
obesity in 2008 doubled compared to 19801 
leading to assumption that what we have done so 
far to prevent and treat obesity was not successful. 
It is suggested that some intrinsic factors affect 
the ability obese/overweight individuals to lose 
weight during a lifestyle intervention.
A growing evidence shown that lipolysis was 
one of the most important factor that induces 
weight loss.4 Lipolysis is initiated in adipocytes 
to release fatty acids (FA) thus can be used as 
the source of energy in negative energy balance.5 
This process is controlled by sympathetic 
nervous system (SNS) via its receptor, beta 
adrenergic receptor (β-AR), and dysfunction of 
this receptor is related to obesity. The role of 
SNS in regulating lipolysis was revealed by an 
observation that denervation of white adipose 
tissue induced hypertrophy6 and electrical 
stimulation of its nerve led to release of fatty 
acids.7 As the mediator of SNS signals, β-AR 
regulates lipolysis through sequential stimulation 
of adenylyl cyclase and protein kinase A (PKA)8 
via a Gs protein. The catalytic subunit of 
activated PKA accesses hormone sensitive lipase 
(HSL) and perilipin then induces release of fatty 
acid and glycerol into circulation.9
In obese individuals, the sensitivity of 
lipolysis response by β-AR was reduced. A study 
by Schiffelers et al. revealed that during β2-AR 
stimulation, obese subjects had lesser increment 
in energy expenditure, plasma Non-esterified 
fatty acid (NEFA) and glycerol level compared 
to lean individuals.10 This is supported by other 
evidence showing that lipolytic noradrenaline 
sensitivity was reduced in obese women 
compared to non-obese women.11 It was also 
observed that obese women had reduction in 
surface density of β2-AR.11
Investigating β-AR induced lipolysis in 
obese individuals is important because weight 
loss intervention was related to changes of 
responsiveness to lipolysis in adipose tissue. 
Various experimental studies in human shown 
that a short-term (up to 4 weeks) very low calorie 
diet (VLCD) was able to increase responsiveness 
of adipose tissue lipolysis to stimulation.12–14 
Similiar to the result, the increment of specific 
β2-AR induced lipolysis was seen after long-term 
(8-15 weeks) low calorie diet.15
FACTORS THAT INFLUENCE LIPOLYSIS
Because lipolysis has an important role 
on lipid mobilization, this process is highly 
regulated. There are some signals with the ability 
to influence lipolysis by increasing or decreasing 
the process through several different pathways. 
Until recently, at least 4 pathways have been 
investigated.20 Chaves et al.20 reviewed that the 
main pathway that induces lipolysis is the cAMP-
dependent protein kinase A (PKA) pathway. 
Additionally, protein kinase B (PKB), protein 
kinase C (PKC) pathway, mitogen activated 
protein kinase (MAPK) pathway, guanylyl 
cyclise and cyclic guanosine monophosphate 
(cGMP) were also responsible in regulation on 
lipolysis.21–24
Catecholamines, the SNS signals which 
includes neurotransmitter norepinephrine and 
hormone epinephrine, are able to stimulate 
lipolysis through PKA pathway.20 When 
cathecolamine binds to β-AR at the surface of 
adipocyte, adenylyl cyclise is activated thus 
intracellular concentration of cAMP increased. 
Increasing cAMP leads to activation of PKA. 
Activated PKA intracellular reacts with perilipin 
1 and hormone sensitive lipase (HSL) thus 
leading to activation of those proteins. In non-
stimulated condition, HSL is located at the 
cytoplasm. However, the phosphorilated HSL 
is able to move to lipid droplet and initiate 
breakdown of triglyceride.20 (Figure 1)
There are some signals that are also able 
to induce lipolysis in human adipose tissue. 
Thyroid-stimulating hormone (TSH) stimulates 
lipolysis using the same pathway as used 
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by cathecolamines, the PKA pathway. This 
protein binds to G-protein-coupled receptor 
inducing stimulation of adenylyl cyclise thus 
increases cAMP level.25 Prostaglandin E2 has 
been reported to affect lipolysis with biphasic 
effect. Low concentration of Prostaglandin E2 
inhibits the  response while high concentration 
of the Prostaglandin E2 leading to stimulatory 
response.26,27
Insulin is secreted by human pancreas 
and has the ability to inhibit lipolysis through 
PKB pathway. The signal is firstly recognized 
by insulin receptors and insulin receptors 
substrates. Those processes then followed by 
several reactions mediated by phosphorilation 
and activation of PDE3B, which decreases 
cAMP levels. The decreasing level of cAMP 
thus reduced PKA activity as well as HSL 
phosporilation. Because less HSL is able to 
translocate into lipid droplet, less lipolysis 
occured in the tissue.20,28 Interestingly, a study 
done by Campbell et al.29 revealed that the ability 
of insulin to suppress lipolysis is impaired in 
obesity. Location of white adipose tissue in 
human body is also related to responsiveness to 
insulin inhibition effect to lipolysis.30
ESTROGEN INHIBITS LIPOLYSIS
The relationship between estrogen and 
adipose tissue metabolism has been investigated 
before. Low estrogen level in menopause women 
was associated with loss of subcutaneous fat 
while male-to-female transsexual receiving 
estrogen treatment increased subcutaneous fat.31,32 
Additionally, when postmanopause women 
receiving hormone replacement therapy the 
epinephrine-stimulated lipolysis was inhibited.33 
In line with the result, estrogen treatment in male-
to-female transsexuals was able to inhibit basal 
lipolysis.34 Some human experiment studies were 
done to clarify the acute effect of estrogen to 
adipose tissue lipolysis. Van Pelt et al.35 showed 
that estrogen can acutely reduce basal lipolysis 
in postmenopause women. Estrogen has also 
proven to acutely inhibit adrenaline-stimulated 
lipolysis in abdominal subcutaneous adipose 
tissue.36
Although various studies suggested that 
lipolysis is inhibited by estrogen signal, 
mechanism underneath this process is still 
unclear. Pedersen et al.37 investigated the 
influence of estrogen to adrenergic receptors in 
vivo from estradiol treated women and in vitro. 
The receptors, including α and β adrenergic 
receptors, were important proteins that initiate 
lipolysis in adipose tissue. From those receptors, 
only α2 adrenergic receptors that is affected by 
estradiol treatment both in vivo and in vitro.37 
In this study, the response of both subcutaneous 
and visceral adipose tissue was also evaluated. 
Interestingly, the effect of estradiol on α2 
adrenergic receptors is only seen in subcutaneous 
adipose tissue.37 The study showed that adipose 
tissue LPL and HSL in vivo, the downstream 
signal of adrenergic receptors, were not affected 
by estradiol.
Estrogen receptor is a nuclear receptor family 
of ligand-activated transcription factor that is 
responsible for physiological action of estrogen. 
This receptor is divided into 2 subtypes, estrogen 
receptor α (ER-α) and estrogen receptor β (ER-
β). Those subtypes are located in different organs 
in human body. ER-α is mostly expressed in 
reproductive tissues, kidney, bone, white adipose 
tissue, and liver, while ER-β is expressed in 
the ovary, prostate, lung, gastrointestinal tract, 
bladder, hematopoietic cells, and the central 
nervous system (CNS).38 In order to investigate 
how estrogen regulate lipolysis, Pedersen et al.37 
also explored which estrogen receptor involved 
in this process. In the study, they reported that the 
effect of estrogen to adipose tissue was mediated 
through ER-α instead of ER-β.37











Figure 1. Regulation of adipose tissue lipolysis
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and non-genomic mechanism. The genomic 
mechanism of estrogen is done via activation of 
estrogen through direct binding of ER dimmers 
to estrogen-responsive elements. This process 
happened in the regulatory regions of estrogen 
target genes thus transcription of the target genes 
could start. On the other hand, estrogen could 
also work through non-genomic mechanism. 
In this process, activated ERs could activates 
of several signalling cascade including protein 
kinase A (PKA), protein kinase C (PKC) and 
mitogen-activated protein kinase (MAPK).39
Investigations have been made to clarify 
the importance of ER-α in adipose tissue 
metabolism as well as its role in obesity. In an 
animal study it was shown that mice lacking 
of ESR1 gene, a gene that responsible for 
production of ER-α, have higher amount of 
adipose tissue compared to wild type.40 In 
population based studies, polymorphism of ESR1 
gene has been associated with BMI and waist 
circumferences.41–45 The genetic expression of 
ESR1 in subcutaneous adipose tissue has been 
measured in premenopausal women. Nilsson et 
al.43 shown that the expression of ESR1 mRNA 
was inversely correlated with BMI. However, 
they found no relationship with variation of that 
gene with subcutaneous adipocyte lipolysis.
CONCLUSION
Although it has been shown that lipolysis is 
regulated by estrogen, the mechanism underneath 
this process is still unclear. Several studies 
have suggested that this is due to the activation 
of ER-α but until recently there is no solid 
evidence to support this hypothesis. Therefore, 
future study should be aimed to investigate the 
role of ER-α on lipolysis in adipose tissue. The 
importance of ER-α signal to affect expression 
of proteins that are involved in adipose tissue 
lipolysis should be addressed.
Additionally, investigation on the effect of 
ER-α agonist to the sensitivity of adrenergic 
receptor to insulin and norephinephrine is 
potential to be done in the future. It has been 
summarized that drugs or treatments targetting 
on beta adrenergic activation is already approved 
and used.8 Thus, new pharmacological and 
nutritional treatment with ability to modulate 
ER-α activity/expression could be used as a 
potential weight loss intervention.
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